We are vaccinating patients ages 12+. Learn more:
Vaccines | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts
Enter the last name, specialty or keyword for your search below.
Work in the Sophie Lanzkron Lab is focused on understanding the barriers to care for adults with sickle cell disease. Our research has shown that despite the approval of hydroxyurea treatment predicted to decrease hospitalizations for sickle cell disease patients' the cost of care has increased significantly in recent years. Research is ongoing to identify the factors that limit access to care for this population.
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
